Compare CZFS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZFS | CNTX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 283.9M |
| IPO Year | 1995 | 2021 |
| Metric | CZFS | CNTX |
|---|---|---|
| Price | $67.38 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 3.1K | ★ 691.6K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ 30.26 | 17.39 |
| EPS | ★ 2.16 | N/A |
| Revenue | ★ $9,881,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.64 | N/A |
| P/E Ratio | $31.35 | ★ N/A |
| Revenue Growth | ★ 2.82 | N/A |
| 52 Week Low | $49.99 | $0.56 |
| 52 Week High | $71.85 | $3.62 |
| Indicator | CZFS | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 27.44 |
| Support Level | $56.79 | $1.39 |
| Resistance Level | $68.35 | $1.55 |
| Average True Range (ATR) | 1.59 | 0.22 |
| MACD | 0.26 | -0.12 |
| Stochastic Oscillator | 38.49 | 1.74 |
Citizens Financial Services Inc is a Pennsylvania-chartered bank and trust company. The company through its banking subsidiary provides banking activities and services for individual, business, governmental and institutional customers. Its activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other specialized financial services. The Trust and Investment division of the Bank offers a full range of client investment, estate, mineral management, and retirement services.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.